CRISPR Therapeutics (CRSP) – Investment Analysts’ Weekly Ratings Updates

CRISPR Therapeutics (NASDAQ: CRSP) recently received a number of ratings updates from brokerages and research firms:

• 10/15/2026 – CRISPR Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/15/2026 – CRISPR Therapeutics is now covered by UBS Group AG. They set a “neutral” rating and a $52.00 price target on the stock.
• 10/9/2026 – CRISPR Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 10/9/2026 – CRISPR Therapeutics had its “buy” rating reaffirmed by UBS Group AG.
• 9/28/2026 – CRISPR Therapeutics had its “market outperform” rating reaffirmed by Citigroup Inc..
• 9/23/2026 – CRISPR Therapeutics was upgraded by William Blair to “strong-buy”.
• 8/31/2026 – CRISPR Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 8/31/2026 – CRISPR Therapeutics had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $80.00 price target on the stock.
• 8/31/2026 – CRISPR Therapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $82.00 price target on the stock.
• 8/25/2026 – CRISPR Therapeutics had its “market outperform” rating reaffirmed by Citigroup Inc..
• 8/25/2026 – CRISPR Therapeutics had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $80.00 price target on the stock.

Insider Transactions at CRISPR Therapeutics

In other news, Director Simeon George sold 14,514 shares of the firm’s stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $49.63, for a total transaction of $720,329.82. Following the transaction, the director directly owned 15,486 shares in the company, valued at approximately $768,570.18. This trade represents a 48.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Samarth Kulkarni sold 47,837 shares of CRISPR Therapeutics stock in a transaction on Monday, October 19th. The shares were sold at an average price of $49.78, for a total transaction of $2,381,325.86. Following the completion of the transaction, the chief executive officer directly owned 311,899 shares in the company, valued at $15,526,332.22. The trade was a 13.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 93,558 shares of company stock worth $4,881,663 in the last three months. Corporate insiders own 5.20% of the company’s stock.

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.